BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity
I'm PortAI, I can summarize articles.
Shares of PepGen rose 21% to $5.53, while Dyne Therapeutics surged 37.5% to $23.54 following Novartis' $12 billion acquisition of Avidity Biosciences. Both companies are developing treatments for rare muscle disorders. RBC Capital Markets predicts Dyne will trade significantly higher due to its similar platform to Avidity, which has a market cap of $2.4 billion. Year-to-date, Dyne is up 1.8% and PepGen has increased 47.8%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments